In adult Fontan patients, treatment with bosentan, an endothelin receptor antaganost (ERA) lowers the pulmonary vascular resistance, which may result in improvement of the cardiopulmonary circulation and functional capacity…
ID
Bron
Verkorte titel
Aandoening
aerobic capacity (peak V’O2)
quality of life
prevalence of arrhythmias
prevalence of protein losing enteropathy
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary objective of this study is to determine changes in aerobic capacity (peak V’O2) in adult patients with a Fontan circulation before and after treatment with the bosentan and compared to non-treated patients.
Achtergrond van het onderzoek
The Fontan procedure is a palliative surgical procedure used in patients with complex congenital heart defects. It involves diverting the venous blood from the right atrium to the pulmonary arteries without passing through the right ventricle. A low pulmonary vascular resistance (PVR) is crucial to preserve the Fontan circulation. Plasma endothelin-1 level, a vasoconstrictor which increases pulmonary vascular resistance, is elevated in patients with Fontan circulation. Treatment with bosentan, an endothelin receptor antagonist (ERA) lowers the pulmonary vascular resistance, which may result in improvement of the cardiopulmonary circulation.
Doel van het onderzoek
In adult Fontan patients, treatment with bosentan, an endothelin receptor antaganost (ERA) lowers the pulmonary vascular resistance, which may result in improvement of the cardiopulmonary circulation and functional capacity.
Onderzoeksopzet
baseline, 3 months, and after 6 months of bosentan treatment.
During bosentan treatment regularly laboratory testing will be performed
Onderzoeksproduct en/of interventie
One group receives a 125 mg tablet of Bosentan twice daily for 6 months. The other group does not receive study medication for the first 3 months, followed by treatment with study medication for 6 months.
Publiek
Department of cardiology <br>
Room F3 – 115
B.J.M. Mulder
Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666051
b.j.mulder@amc.uva.nl
Wetenschappelijk
Department of cardiology <br>
Room F3 – 115
B.J.M. Mulder
Meibergdreef 9
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5666051
b.j.mulder@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1. All adult Fontan patients are potentially eligible for this study.
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
- Patients are not eligible for this study if the following inclusion criteria apply:
1. Systemic arterial pressure < 85 mmHg
2. Incapable of giving informed consent
3. Hypersensitivity to bosentan or any of its help substances
4. Current treatment with bosentan or treatment for pulmonary arterial hypertension
5. Moderate to severe liver disease: Child-Pugh class B or C
6. Raised plasma transaminases level > three times limiting value
7. Simultaneous use of cyclosporine A
8. Desire to have children within the study period or women who do not use reliable contraceptive methods
9. Pregnant or nursing women
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL1487 |
| NTR-old | NTR1557 |
| Ander register | : 03602 |
| ISRCTN | ISRCTN wordt niet meer aangevraagd |